D.A. Davidson & CO. lessened its holdings in DexCom, Inc. (NASDAQ:DXCM) by 2.5% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 3,250 shares of the medical device company’s stock after selling 85 shares during the period. D.A. Davidson & CO.’s holdings in DexCom were worth $237,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Vanguard Group Inc. raised its stake in DexCom by 4.2% in the 1st quarter. Vanguard Group Inc. now owns 6,596,294 shares of the medical device company’s stock valued at $558,904,000 after acquiring an additional 263,543 shares during the period. BlackRock Inc. raised its stake in DexCom by 5.5% in the 2nd quarter. BlackRock Inc. now owns 4,391,404 shares of the medical device company’s stock valued at $321,232,000 after acquiring an additional 230,542 shares during the period. Janus Capital Management LLC raised its stake in DexCom by 12.2% in the 1st quarter. Janus Capital Management LLC now owns 4,001,971 shares of the medical device company’s stock valued at $339,083,000 after acquiring an additional 436,162 shares during the period. Ameriprise Financial Inc. raised its stake in DexCom by 18.2% in the 2nd quarter. Ameriprise Financial Inc. now owns 3,948,468 shares of the medical device company’s stock valued at $288,669,000 after acquiring an additional 607,972 shares during the period. Finally, Bank of New York Mellon Corp raised its stake in DexCom by 27.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 3,242,928 shares of the medical device company’s stock valued at $237,221,000 after acquiring an additional 696,199 shares during the period.

DXCM has been the topic of a number of research analyst reports. Barclays PLC restated an “equal weight” rating and issued a $60.00 price target (down previously from $76.00) on shares of DexCom in a research note on Thursday, September 28th. Citigroup Inc. cut DexCom from an “outperform” rating to a “market perform” rating in a research report on Thursday, September 28th. BidaskClub cut DexCom from a “buy” rating to a “hold” rating in a research report on Wednesday, July 5th. Zacks Investment Research upgraded DexCom from a “sell” rating to a “hold” rating in a research report on Monday, August 14th. Finally, Leerink Swann reiterated a “buy” rating and set a $57.00 price objective (down previously from $85.00) on shares of DexCom in a research report on Friday, September 29th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and fourteen have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $72.19.

Shares of DexCom, Inc. (NASDAQ:DXCM) opened at 48.10 on Thursday. The stock’s 50 day moving average price is $69.11 and its 200 day moving average price is $72.43. The firm’s market capitalization is $4.16 billion. DexCom, Inc. has a 12-month low of $42.62 and a 12-month high of $88.80.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Tuesday, August 1st. The medical device company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.07. DexCom had a negative return on equity of 27.90% and a negative net margin of 10.27%. The company had revenue of $170.60 million for the quarter, compared to analyst estimates of $166.54 million. During the same period in the previous year, the company posted ($0.24) EPS. The firm’s revenue for the quarter was up 24.3% compared to the same quarter last year. Equities research analysts expect that DexCom, Inc. will post ($0.80) earnings per share for the current year.

In related news, CEO Kevin R. Sayer sold 6,000 shares of the business’s stock in a transaction dated Wednesday, July 12th. The stock was sold at an average price of $71.86, for a total transaction of $431,160.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Steven Robert Pacelli sold 1,450 shares of the business’s stock in a transaction dated Monday, July 24th. The stock was sold at an average price of $69.47, for a total value of $100,731.50. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 32,223 shares of company stock worth $2,285,138. 1.70% of the stock is currently owned by corporate insiders.

COPYRIGHT VIOLATION WARNING: This report was first reported by Watch List News and is owned by of Watch List News. If you are viewing this report on another domain, it was copied illegally and reposted in violation of United States & international trademark and copyright laws. The legal version of this report can be accessed at https://www.watchlistnews.com/dexcom-inc-dxcm-shares-sold-by-d-a-davidson-co/1609557.html.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.